Supplementary Role of Immunological Indicators in the Diagnosis and Prognosis of Pneumocystis Pneumonia in Non-HIV Immunocompromised Patients

References

• Charpentier E, Marques C, Ménard S, et al. New insights into blood circulating lymphocytes in human pneumocystis pneumonia. J Fungi. 2021;7(8):652. doi:10.3390/jof7080652
   Web of Science ®Google Scholar
• Chen M, Tian X, Qin F, et al. Pneumocystis pneumonia in patients with autoimmune diseases: a retrospective study focused on clinical characteristics and prognostic factors related to death. PLoS One. 2015;10(9):e0139144. doi:10.1371/journal.pone.0139144
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang X, Sun T, Fan G, Zhan Q, Weng L. Non-HIV-infected patients with Pneumocystis pneumonia in the intensive care unit: a bicentric, retrospective study focused on predictive factors of in-hospital mortality. Clin Respir J. 2022;16:152–161. doi:10.1111/crj.13463
   PubMed Web of Science ®Google Scholar
• Roblot F, Le Moal G, Godet C, et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J Infect. 2003;47(1):19–27. doi:10.1016/S0163-4453(03)00038-0
   Web of Science ®Google Scholar
• Ko Y, Jeong BH, Park HY, et al. Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients. J Crit Care. 2014;29(3):356–361. doi:10.1016/j.jcrc.2013.12.005
   PubMed Web of Science ®Google Scholar
• Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest. 2000;118(3):712–720. doi:10.1378/chest.118.3.712
   PubMed Web of Science ®Google Scholar
• Rong HM, Li T, Zhang C, et al. IL-10-producing B cells regulate Th1/Th17-cell immune responses in Pneumocystis pneumonia. Am J Physiol Lung Cell Mol Physiol. 2019;316(1):L291–l301. doi:10.1152/ajplung.00210.2018
   PubMed Web of Science ®Google Scholar
• Zhang NN, Huang X, Feng HY, et al. Circulating and pulmonary T-cell populations driving the immune response in non-HIV immunocompromised patients with Pneumocystis jirovecii pneumonia. Int J Med Sci. 2019;16(9):1221–1230. doi:10.7150/ijms.34512
   Web of Science ®Google Scholar
• Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol. 2006;176(10):6147–6154. doi:10.4049/jimmunol.176.10.6147
   Web of Science ®Google Scholar
• Hoyt TR, Dobrinen E, Kochetkova I, Meissner N, Deepe GS. B cells modulate systemic responses to Pneumocystis murina lung infection and protect on-demand hematopoiesis via T cell-independent innate mechanisms when type I interferon signaling is absent. Infect Immun. 2015;83(2):743–758. doi:10.1128/IAI.02639-14
   Web of Science ®Google Scholar
• Rapaka RR, Ricks DM, Alcorn JF, et al. Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J Exp Med. 2010;207(13):2907–2919. doi:10.1084/jem.20100034
   Web of Science ®Google Scholar
• Martin-Garrido I, Carmona EM, Specks U, Limper AH. Pneumocystis pneumonia in patients treated with rituximab. Chest. 2013;144(1):258–265. doi:10.1378/chest.12-0477
   PubMed Web of Science ®Google Scholar
• Yamani MH, Avery RK, Mawhorter SD, et al. Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infection. J Heart Lung Transplant. 2001;20(4):425–430. doi:10.1016/S1053-2498(00)00331-4
   Web of Science ®Google Scholar
• Zhang XQ, Lei Y, Tan XL, et al. Optimization of early antimicrobial strategies for lung transplant recipients based on metagenomic next-generation sequencing. Front Microbiol. 2022;13:839698. doi:10.3389/fmicb.2022.839698
   Web of Science ®Google Scholar
• van de Geijn GJ, van Rees V, van Pul-Bom N, et al. Leukoflow: multiparameter extended white blood cell differentiation for routine analysis by flow cytometry. Cytometry Part A. 2011;79(9):694–706.
   Google Scholar
• Iriart X, Witkowski B, Courtais C, et al. Cellular and cytokine changes in the alveolar environment among immunocompromised patients during Pneumocystis jirovecii infection. Med Mycol. 2010;48(8):1075–1087. doi:10.3109/13693786.2010.484027
   Web of Science ®Google Scholar
• Tang G, Tong S, Yuan X, et al. Using routine laboratory markers and immunological indicators for predicting Pneumocystis jiroveci pneumonia in immunocompromised patients. Front Immunol. 2021;12:652383. doi:10.3389/fimmu.2021.652383
   PubMed Web of Science ®Google Scholar
• Struijk GH, Gijsen AF, Yong SL, et al. Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation. Nephrol Dialysis Transplant. 2011;26(10):3391–3398. doi:10.1093/ndt/gfr048
   Web of Science ®Google Scholar
• Li Y, Ghannoum M, Deng C, et al. Pneumocystis pneumonia in patients with inflammatory or autoimmune diseases: usefulness of lymphocyte subtyping. Int J Infect Dis. 2017;57:108–115. doi:10.1016/j.ijid.2017.02.010
   PubMed Web of Science ®Google Scholar
• Ling C, Qian S, Wang Q, et al. Pneumocystis pneumonia in non-HIV children: a 10-year retrospective study. Clin Respir J. 2018;12(1):16–22. doi:10.1111/crj.12467
   PubMed Web of Science ®Google Scholar
• Weng L, Huang X, Chen L, et al. Prognostic factors for severe Pneumocystis jiroveci pneumonia of non-HIV patients in intensive care unit: a bicentric retrospective study. BMC Infect Dis. 2016;16(1):528. doi:10.1186/s12879-016-1855-x
   Web of Science ®Google Scholar
• Braun WE, Avery R, Gifford RW, Straffon RA. Life after 20 years with a kidney transplant: redefined disease profiles and an emerging nondiabetic vasculopathy. Transplant Proc. 1997;29(1–2):247–249. doi:10.1016/S0041-1345(96)00082-6
   Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. doi:10.3389/fimmu.2014.00520
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496–1502. doi:10.1136/annrheumdis-2012-201956
   PubMed Web of Science ®Google Scholar
• Parmentier C, Delbet JD, Decramer S, Boyer O, Hogan J, Ulinski T. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2020;35(3):455–462. doi:10.1007/s00467-019-04398-1
   Web of Science ®Google Scholar
• Colucci M, Carsetti R, Serafinelli J, et al. Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome. Front Immunol. 2019;10:1653. doi:10.3389/fimmu.2019.01653
   Web of Science ®Google Scholar
• Freiwald T, Büttner S, Cheru NT, et al. CD4(+) T cell lymphopenia predicts mortality from Pneumocystis pneumonia in kidney transplant patients. Clin Transplant. 2020;34(9):e13877. doi:10.1111/ctr.13877
   Web of Science ®Google Scholar
• Shearer WT, Dunn E, Notarangelo LD, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014;133(4):1092–1098. doi:10.1016/j.jaci.2013.09.044
   PubMed Web of Science ®Google Scholar
• Bhagwat SP, Gigliotti F, Xu H, Wright TW. Contribution of T cell subsets to the pathophysiology of Pneumocystis-related immunorestitution disease. Am J Physiol Lung Cell Mol Physiol. 2006;291(6):L1256–66. doi:10.1152/ajplung.00079.2006
   Web of Science ®Google Scholar
• Jin F, Xie J, Wang HL. Lymphocyte subset analysis to evaluate the prognosis of HIV-negative patients with pneumocystis pneumonia. BMC Infect Dis. 2021;21(1):441. doi:10.1186/s12879-021-06124-5
   Web of Science ®Google Scholar
• Beck JM, Newbury RL, Palmer BE, Warnock ML, Byrd PK, Kaltreider HB. Role of CD8+ lymphocytes in host defense against Pneumocystis carinii in mice. J Lab Clin Med. 1996;128(5):477–487. doi:10.1016/S0022-2143(96)90044-X
   Web of Science ®Google Scholar
• Ruan S, Samuelson DR, Assouline B, Morre M, Shellito JE. Treatment with interleukin-7 restores host defense against pneumocystis in CD4+ T-lymphocyte-depleted mice. Infect Immun. 2016;84(1):108–119. doi:10.1128/IAI.01189-15
   Web of Science ®Google Scholar
• Gigliotti F, Crow EL, Bhagwat SP, Wright TW. Sensitized CD8+ T cells fail to control organism burden but accelerate the onset of lung injury during Pneumocystis carinii pneumonia. Infect Immun. 2006;74(11):6310–6316. doi:10.1128/IAI.00668-06
   Web of Science ®Google Scholar
• Myers RC, Dunaway CW, Nelson MP, Trevor JL, Morris A, Steele C. STAT4-dependent and -independent Th2 responses correlate with protective immunity against lung infection with Pneumocystis murina. J Immunol. 2013;190(12):6287–6294. doi:10.4049/jimmunol.1300431
   Web of Science ®Google Scholar
• McAllister F, Steele C, Zheng M, et al. T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice. J Immunol. 2004;172(2):1132–1138. doi:10.4049/jimmunol.172.2.1132
   Web of Science ®Google Scholar